News >

Pembrolizumab Improves Survival in PD-L1+ Esophageal Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Nov 14, 2018

Dr. Roy Baynes

Roy Baynes, MD, PhD
Second-line treatment with pembrolizumab (Keytruda) improved overall survival (OS) versus chemotherapy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma whose tumors expressed PD-L1, according to topline phase III findings announced by Merck (MSD), the developer of the PD-1 inhibitor.1

“In this pivotal trial, Keytruda resulted in a statistically significant and clinically meaningful improvement over standard chemotherapy in overall survival for patients with advanced esophageal or esophagogastric junction carcinoma whose tumors express PD-L1 with a CPS of 10 or greater,” Roy Baynes, MD, senior vice president and head of global clinical development, chief medical officer, of Merck Research Laboratories, said in the news release. “This marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti–PD-1 therapy has achieved overall survival for this patient population.”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x